Figure 2.
Changes over 1.5 years in the percentages of patients to whom MBD-related drugs were prescribed. (a) Percentages of patients to whom intravenous vitamin D (calcitriol or maxacalcitol) or oral vitamin D (falecalcitriol, calcitriol, or alphacalcidol) were prescribed. (b) Percentages of patients to whom calcium-based phosphate binder (calcium carbonate) or non-calcium-based phosphate binder (sevelamer hydrochloride or lanthanum carbonate) were prescribed. Lanthanum carbonate became available in Japan at the end of the 1.5 years (April, 2009) and was prescribed to only a few patients and only at visit 6. (c) Percentages of patients to whom cinacalcet was prescribed. Cinacalcet became available at the beginning of the 1.5 years (January, 2008).